BENITEC BIOPHAR/S (NASDAQ:BNTC) Shares Cross Below Fifty Day Moving Average of $4.65

Share on StockTwits

Shares of BENITEC BIOPHAR/S (NASDAQ:BNTC) passed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $4.65 and traded as low as $3.20. BENITEC BIOPHAR/S shares last traded at $3.20, with a volume of 9,000 shares.

Separately, ValuEngine upgraded BENITEC BIOPHAR/S from a “hold” rating to a “buy” rating in a research note on Tuesday, December 3rd.

The company has a current ratio of 20.29, a quick ratio of 7.10 and a debt-to-equity ratio of 0.02. The stock has a fifty day moving average of $4.63 and a 200 day moving average of $3.38.

A hedge fund recently bought a new stake in BENITEC BIOPHAR/S stock. Sabby Management LLC bought a new position in shares of BENITEC BIOPHAR/S (NASDAQ:BNTC) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 1,365,615 shares of the biotechnology company’s stock, valued at approximately $971,000. BENITEC BIOPHAR/S accounts for approximately 0.5% of Sabby Management LLC’s investment portfolio, making the stock its 11th biggest holding. Sabby Management LLC owned 106.69% of BENITEC BIOPHAR/S as of its most recent SEC filing. Institutional investors own 8.47% of the company’s stock.

About BENITEC BIOPHAR/S (NASDAQ:BNTC)

Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B.

Featured Article: How liquidity affects the bid-ask spread

Receive News & Ratings for BENITEC BIOPHAR/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BENITEC BIOPHAR/S and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2020 BBNS.